> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# $60 Million Surgical Mesh Agreement with 49 States
- URL: https://www.fdaweb.com/60-million-surgical-mesh-agreement-with-49-states/
- Published: 2020-09-24T12:00:00.000Z
- Updated: 2026-09-14T16:30:06.000Z
- Author: David McFarland
- Tags: Devices, #legacy-id-D5147730

A coalition of 49 attorneys general have announced a [multistate agreement](https://ag.ny.gov/sites/default/files/09.24.2020%5Fbard%5Fconsent%5Forder%5Fand%5Fjudgment.pdf?ref=fdaweb.com) that requires C.R. Bard and its parent company, Becton, Dickinson, to pay $60 million for the “deceptive marketing of transvaginal surgical mesh devices that endangered the health of women across New York and the rest of the nation,” according to a [release](https://ag.ny.gov/press-release/2020/attorney-general-james-helps-recover-60-million-company-endangered-womens-health?ref=fdaweb.com) from New York attorney general **Letitia James**. A multistate investigation found that Bard violated state consumer protection laws by “misrepresenting the safety and effectiveness of the devices and failing to sufficiently disclose risks associated with their use,” she said. Transvaginal surgical mesh is a synthetic implant to support pelvic organs in women who suffer from stress urinary incontinence or pelvic organ prolapse.

The multistate investigation found that Bard misrepresented or failed to adequately disclose the device’s serious risks, such as chronic pain, scarring and shrinking of bodily tissue, painful sexual relations, and recurring infections, among other complications. “Evidence shows that C. R. Bard was aware of the possibility for serious medical complications but did not provide sufficient warnings to consumers or surgeons who implanted the devices,” James said.